Bharat Biotech published the interim efficacy report of phase 3 clinical trial on its COVID-19 vaccine, officially known as Covaxin. The indigenous COVID-19 vaccine is found to be 81 per cent effective in preventing the virus

Government data shows that only 10% of about 12.6 million people immunised in India have taken the COVAXIN shot, which was found to be 81% effective in an interim analysis of the late-stage trial, its developer Bharat Biotech said

Digital media norms to be administered by Centre, not states The Information and Broadcasting (I&B) Ministry on Wednesday issued memorandum to states and union territories saying that the new rules for digital news publishers and over-the-top (OTT) platforms are to be administered by the Centre, not the states. The government had notified the Information Technology (Intermediary Guidelines and Digital Media Ethics Codes) Rules, 2021 on February 25. Defence equipment sales to India sho...

So far, the Pfizer-BioNTtech and Moderna vaccines, made through a novel platform technology never used in humans before, are proven to have maximum efficacy

The interim efficacy trend of 81 per cent, analysed as per the protocol approved by the Drugs Controller General of India, puts it at par with other global front-runner vaccines, stated ICMR

Data from 25,800 participants who received a vaccine or placebo in 1:1 ratio showed that the vaccine was well-tolerated; Bharat Biotech said the trial conducted with ICMR was the largest in India

The real-world study involved around 1.2 million people in Israel. Pfizer vaccine has also proved to be effective against B.1.1.7 variant, also known as the UK variant of coronavirus

Coronavirus vaccine: The Covid-19 vaccine candidate of Novavax is being studied in two ongoing pivotal Phase 3 clinical trials: in the United States and Mexico, as well as in the United Kingdom

The dosing mishap was presented to the trial participants in a letter dated June 8 as an opportunity for University of Oxford researchers to learn how well the vaccine works at different doses

Sputnik V is undergoing Phase-3 trials in India currently which is expected to be completed by February

The American biotech company said its two-antibody cocktail, REGEN-COV, caused a 100% reduction in symptomatic infection and roughly 50% lower overall rates of infection

Russia began testing EpiVacCorona, which is being developed by Siberia's Vector Institute, in November

The phase-2 trials of Zydus Cadila's coronavirus vaccine had been conducted in around 1,000 healthy adults

India on Sunday granted emergency approval to Bharat Biotech's COVAXIN but faced questions after taking the step without publishing efficacy data for the homegrown coronavirus vaccine

COVID-19 vaccines in India: Oxford-AstraZeneca's coronavirus vaccine Covishield and Bharat Biotech's COVID vaccine Covaxin will be India's first vaccines

The university said it had explored two dosing regimes in early stage trials, a full-dose/full-dose regime and a full-dose/half-dose regime, investigated as a possible 'dose sparing' strategy

GSK said phase 1/2 interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years but there was an insufficient response in older adults

AstraZeneca is currently seeking regulatory approval in many countries across the world. The company hopes that it will get the approval of MHRA, UK's regulator, within the next few weeks

Medical journal Lancet pointed out that surprisingly the COVID-19 vaccine candidate was 90 per cent effective when a low dose was followed by a full dose

AIDAN wanted to know the exact processes and parameters for restricted emergency use approval of COVID-19 vaccine candidates in India, and whether and under what conditions interim results can be sufficient for seeking such an approval